Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Rating)’s share price shot up 6.8% on Wednesday . The company traded as high as $3.28 and last traded at $3.28. 8,425 shares were traded during mid-day trading, a decline of 99% from the average session volume of 690,960 shares. The stock had previously closed at $3.07.
Separately, StockNews.com lowered shares of Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 20th.
The stock has a fifty day simple moving average of $3.68. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.46 and a current ratio of 2.31. The firm has a market capitalization of $1.01 billion, a PE ratio of 153.50, a price-to-earnings-growth ratio of 0.17 and a beta of 1.17.
Amneal Pharmaceuticals Company Profile (NASDAQ:AMRX)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- The Insiders Are Selling Chevron But You Shouldn’t
- Two Retailers The Analysts Are Buying
- Under-The-Radar RF Industries Is A Steal At These Prices
- Procter & Gamble Stock Continues to Be Resilient Despite Turmoil
- Insiders Sell Tractor Supply Company, Oh No!
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.